Agility Life Sciences

Agility Life Sciences is an award-winning formulation development contract development and manufacturing organisation (CDMO) based in Nottingham, United Kingdom.

Established in 2012, Agility Life Sciences specialises in transforming challenging pharmaceutical molecules into effective formulations, enhancing their success rates in preclinical studies and expediting their progression to clinical and commercial stages.

Key Products and Services:

• Formulation Development: Expertise in creating formulations for small molecules and peptides across various administration routes, including oral, ocular, intranasal, and topical.
• Overcoming Drug Delivery Challenges: Addressing issues such as poor solubility, permeability, stability, and release profiles to optimise drug efficacy.
• Advanced Drug Delivery Systems: Development of lipid nanoparticle and liposomal formulations for targeted drug delivery, including strategies to cross the blood-brain barrier.
• Release Profile Customisation: Designing immediate, controlled, and sustained-release formulations tailored to specific therapeutic needs.
• Preclinical and Clinical Prototypes: Providing formulations and analytical methods suitable for preclinical safety and efficacy studies, including GLP toxicology studies, as well as clinical and commercial prototypes.

Agility Life Sciences' comprehensive approach ensures that all intellectual property generated during projects remains with the client, reflecting their commitment to client-centric service and innovation in pharmaceutical development.